PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34342835-1 2021 Budesonide/glycopyrronium/formoterol (BREZTRI AEROSPHERE ; TRIXEO AEROSPHERE ) is an inhaled fixed-dose combination of the inhaled corticosteroid (ICS) budesonide, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the long-acting beta2-agonist (LABA) formoterol fumarate approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Formoterol Fumarate 26-36 ATPase H+ transporting V0 subunit a2 Homo sapiens 252-257 34725715-7 2021 RESULTS: Isoprenaline and formoterol (both beta2 agonists) induced IL-6, but not IL-8, release, which could be inhibited by ICI 118,551 (beta2 antagonist). Formoterol Fumarate 26-36 ATPase H+ transporting V0 subunit a2 Homo sapiens 43-48 34725715-7 2021 RESULTS: Isoprenaline and formoterol (both beta2 agonists) induced IL-6, but not IL-8, release, which could be inhibited by ICI 118,551 (beta2 antagonist). Formoterol Fumarate 26-36 ATPase H+ transporting V0 subunit a2 Homo sapiens 137-142 34137664-1 2021 Introduction: Aclidinium/formoterol is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) dual bronchodilator used as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Formoterol Fumarate 25-35 ATPase H+ transporting V0 subunit a2 Homo sapiens 98-103 35525480-1 2022 INTRODUCTION: An extrafine formulation of the inhaled corticosteroid beclometasone dipropionate (BDP) plus the long-acting beta2-agonist formoterol fumarate (FF) has been available for years via a pressurised metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease. Formoterol Fumarate 137-156 ATPase H+ transporting V0 subunit a2 Homo sapiens 123-128 35525480-1 2022 INTRODUCTION: An extrafine formulation of the inhaled corticosteroid beclometasone dipropionate (BDP) plus the long-acting beta2-agonist formoterol fumarate (FF) has been available for years via a pressurised metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease. Formoterol Fumarate 158-160 ATPase H+ transporting V0 subunit a2 Homo sapiens 123-128 33474708-6 2021 Instead, GINA now recommends an anti-inflammatory rescue/reliever approach for adult and adolescent patients, based on the combination of an inhaled corticosteroid with a rapid onset beta2-agonist such as formoterol. Formoterol Fumarate 205-215 ATPase H+ transporting V0 subunit a2 Homo sapiens 183-188 33210444-1 2021 As of 2020, use of beta2-agonist salmeterol is restricted by the World Anti-Doping Agency (WADA) and is only permitted by inhalation at therapeutic doses not exceeding 200 mug in 24 h. In contrast to beta2-agonists salbutamol and formoterol, WADA has not established a urine threshold for salmeterol despite its muscle hypertrophic actions observed in animals. Formoterol Fumarate 230-240 ATPase H+ transporting V0 subunit a2 Homo sapiens 19-24 33251412-6 2020 Our results indicated that combining dexamethasone with fast long-acting beta-2 adrenergic agonists (LABAs), such as formoterol and salmeterol, can ease respiratory symptoms hastily, until dexamethasone"s anti-inflammatory and immunosuppressant effects kick in. Formoterol Fumarate 117-127 ATPase H+ transporting V0 subunit a2 Homo sapiens 73-79 33603341-0 2021 Erratum: Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting beta2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]. Formoterol Fumarate 20-30 ATPase H+ transporting V0 subunit a2 Homo sapiens 140-145 33273813-2 2020 Formoterol is a highly selective and potent beta2-agonist that relaxes airway smooth muscle to significantly improve lung function. Formoterol Fumarate 0-10 ATPase H+ transporting V0 subunit a2 Homo sapiens 44-49 32330364-6 2020 Formoterol and BRL 37344, which are agonists of beta2 - and beta3 -adrenoceptor, respectively, significantly increased MMP1 and MMP2 expression under 70 cm H2 O. Formoterol Fumarate 0-10 ATPase H+ transporting V0 subunit a2 Homo sapiens 48-53 32444401-7 2020 Participants randomised to as-needed budesonide-formoterol took higher equivalent doses of beta2-agonist both overall (median number of actuations 0.8 versus 0.3 per day respectively) and in response to worsening asthma (total number of "overuse days" of >8 or >16 actuations of budesonide-formoterol or terbutaline 33 versus 10 respectively). Formoterol Fumarate 48-58 ATPase H+ transporting V0 subunit a2 Homo sapiens 91-96 32253054-1 2020 PURPOSE: The triple combination therapy budesonide/glycopyrrolate/formoterol fumarate in a metered dose inhaler (BGF MDI), formulated by using innovative co-suspension delivery technology, is a new inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta2-agonist fixed-dose combination for the maintenance treatment of COPD. Formoterol Fumarate 66-85 ATPase H+ transporting V0 subunit a2 Homo sapiens 267-272 32411580-3 2020 In a clinical setting, beta2-adrenergic agonists, such as salbutamol and formoterol, are used for the treatment of asthma attacks or exacerbation to release the airway obstruction. Formoterol Fumarate 73-83 ATPase H+ transporting V0 subunit a2 Homo sapiens 23-28 31749061-0 2020 Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting beta2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care. Formoterol Fumarate 125-144 ATPase H+ transporting V0 subunit a2 Homo sapiens 88-93 30536718-8 2019 We demonstrate that PGE2 -induced heterologous receptor desensitization responsible for tachyphylaxis to short- (salbutamol) or long- (formoterol) beta2 -agonists (measured by cAMP release) can be reversed by the EP2 receptor antagonist PF-04418948. Formoterol Fumarate 135-145 ATPase H+ transporting V0 subunit a2 Homo sapiens 147-152 30836453-1 2019 While studies have demonstrated substantial differences in beta2 -adrenergic agonist enantiomer pharmacology, enantioselective disposition of long-acting beta2 -adrenergic ligand racemic (rac)-formoterol in blood is inadequately explored after inhaled therapy given analytical challenges. Formoterol Fumarate 193-203 ATPase H+ transporting V0 subunit a2 Homo sapiens 154-159 30836453-8 2019 Furthermore, formoterol induced an approximately two-fold increase in muscle p-PKASer/thr phosphorylation (p < 0.01), indicating a substantial beta2 -adrenergic response. Formoterol Fumarate 13-23 ATPase H+ transporting V0 subunit a2 Homo sapiens 143-148